12.05.08
Nigel McBean has been named vice president and director of operations at IndiPharm's operational headquarters in Mumbai, India. Mr. McBean will be responsible for all operational activities, including identification and recruitment of investigators and clinical research sites, regulatory approvals, project and site management, monitoring, and pharmacovigilance. He will be based in Mumbai and will be responsible for expanding and managing the staff for the India-based operations.
Mr. McBean has experience managing clinical research projects in Asia and the Pacific, ranging in size from 20 patient single-center studies to 5000 plus patient global studies. He has managed global clinical projects in North and South America, Africa, the Middle East and Europe across multiple therapeutic areas including infectious diseases, oncology, cardiovascular, dermatology, urology and immunology.
Mr. McBean was previously the director of Multi-Centre Research for PRACS Institute Ltd. (now part of the Cetero Research Group), where he implemented an electronic clinical management system to support projects from inception to final clinical report. He also developed a clinical database that evaluates potential sites based on investigator details and experience, the facilities and staff, local regulatory turnaround time, recruitment performance, patient demographics, and site availability.
James A. Bannon, IndiPharm’s chairman of the board said, “Western clients will benefit from Nigel’s global clinical trial management experience and his direct leadership of our Indian operations in meeting the project timelines, quality standards and regulatory expectations.” The foundation of the Indian operations is the Indian Investigator Network (IIN), which will be managed by Mr. McBean. The IIN is a network of clinical investigators with extensive experience in multinational clinical trials in a wide range of therapeutic areas.
Mr. McBean has experience managing clinical research projects in Asia and the Pacific, ranging in size from 20 patient single-center studies to 5000 plus patient global studies. He has managed global clinical projects in North and South America, Africa, the Middle East and Europe across multiple therapeutic areas including infectious diseases, oncology, cardiovascular, dermatology, urology and immunology.
Mr. McBean was previously the director of Multi-Centre Research for PRACS Institute Ltd. (now part of the Cetero Research Group), where he implemented an electronic clinical management system to support projects from inception to final clinical report. He also developed a clinical database that evaluates potential sites based on investigator details and experience, the facilities and staff, local regulatory turnaround time, recruitment performance, patient demographics, and site availability.
James A. Bannon, IndiPharm’s chairman of the board said, “Western clients will benefit from Nigel’s global clinical trial management experience and his direct leadership of our Indian operations in meeting the project timelines, quality standards and regulatory expectations.” The foundation of the Indian operations is the Indian Investigator Network (IIN), which will be managed by Mr. McBean. The IIN is a network of clinical investigators with extensive experience in multinational clinical trials in a wide range of therapeutic areas.